The information on this site does not replace your doctor's advice; only your doctor can assess the benefits and risks of therapy to determine whether LDL Apheresis using the LIPOSORBER® system is right for you. Your doctor also can provide a complete description of reported side effects associated with this treatment.
The LIPOSORBER LA-15 LDL Apheresis System is used for performing LDL Apheresis to acutely remove LDL-C (“bad cholesterol”) from the patient’s plasma. It is comprised of a tubing set, a hollow fiber plasma separator (Sulflux KP-05) and two dextran sulfate LDL-adsorption columns (Liposorber LA-15), which is our patented technology. The MA-03 is the computer-automated system that controls the entire LDL Apheresis procedure.
The LIPOSORBER LA-15 System is approved by the FDA and indicated for use in performing low density lipoprotein cholesterol (LDL-C) apheresis to acutely remove LDL-C from the plasma of the following high risk patient populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated:
Group A: | Functional Hypercholesterolemic Homozygotes with LDL-C > 500 mg/dL; |
Group B: | Functional Hypercholesterolemic Heterozygotes with LDL-C ≥ 300 mg/dL; and |
Group C: | Functional Hypercholesterolemic Heterozygotes with LDL-C ≥ 160 mg/dL and either documented coronary heart disease or documented peripheral arterial disease. |
|
|
© Copyright Kaneka Pharma America, LLC . All rights reserved.
The information on this site is intended for U.S. residents only.